ArticleArchives of dermatological research2025
Trend analysis and cross nations inequality analysis of infectious skin diseases from 1990 to 2021.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The skin serves as a crucial barrier against microbial invasion, but breaches in this barrier can lead to infectious skin diseases (ISD). ISD, including bacterial (BSD), fungal (FSD) and viral Skin Disease (VSD), pose significant global health challenges. Age-standardized and age specific incidence, prevalence, and lived with disability (YLDs) data for ISD were sourced from the Global Burden of Disease Study 2021 (GBD 2021) and demographic data from the United Nations. We utilized linear regression to analyze the prevalence trends and the Average Annual Percentage Change (AAPC) for BSD, FSD and VSD. Log transformation of prevalence rates addressed heteroscedasticity. Cross-national inequality was assessed using concentration and slope indices based on SDI. From the prevalence perspective, FSD continues to rank first, with a prevalence rate of 7789.55 (95% CI 7059.28 to 8583.54) in 2021. Interestingly, VSD overtakes BSD, with a prevalence rate of 1781.31 (95% CI 1733.08 to 1835.16), while BSD has a prevalence rate of 473.98 (95% CI 463.37 to 484.64). Next, looking at YLDs, VSD rises to the first position in 2021, with YLDs rate of 54.77 (95% CI 34.83 to 81.77). FSD comes next, with YLDs rate of 43.39 (95% CI 17.79 to 89.10). Lastly, BSD has YLDs rate of 4.21 (95% CI 2.36 to 7.20). The rate of YLDs for FSD is primarily concentrated among the elderly, while VSD are concentrated among children. There is no significant difference for BSD. The burden is greater for males than females. The prevalence of BSD and FSD is negatively correlated with the Socio-demographic Index (SDI), with the burden primarily concentrated in low SDI countries. VSD shows a positive correlation, mainly concentrated in high SDI countries. We discovered that the global impact of ISD remains significant. Both BSD and FSD are increasing, while VSD are decreasing. FSD is more common among the elderly, whereas VSD predominantly affects children. BSD and FSD are primarily found in less developed areas such as Africa, whereas VSD is more prevalent in developed regions like Europe and North America. ISD cases are also increasing in the Middle East and South America. To reduce the burden of ISD, it is crucial to improve global hygiene standards, boost vaccination rates against viruses, and strictly regulate the use of antimicrobial drugs.
Indexed as
Identifiers
39775948What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.